Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study
| Autor: | Clara Duran, Aurélien Dinh, Thomas W. Bauer, Marine de Laroche, Claire Rempenault, Elsa Salomon, Frédérique Bouchand, Morgan Matt, Valentine Pagis, Simona Berbescu, Latifa Noussair, Benjamin Davido, Martin Rottman, Christophe Nich |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Microbiology (medical) Spondylodiscitis Tazobactam medicine.medical_specialty Bone and joint infection medicine.drug_class Avibactam 030106 microbiology Immunology Antibiotics Resistance Ceftazidime Microbial Sensitivity Tests Multidrug resistance Microbiology Cohort Studies 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Ceftazidime/avibactam Internal medicine medicine Humans Immunology and Allergy 030212 general & internal medicine Aged business.industry Middle Aged medicine.disease Ceftolozane/tazobactam QR1-502 Cephalosporins chemistry Ceftolozane business BJI Azabicyclo Compounds medicine.drug Cohort study |
| Zdroj: | Journal of Global Antimicrobial Resistance, Vol 25, Iss, Pp 282-286 (2021) |
| ISSN: | 2213-7165 |
| Popis: | Background . Ceftazidime/Avibactam (C/A) and Ceftolozane/Tazobactam (C/T) are two novel antibacterial agents with a known efficacy on Gram-negative bacteria (GNB). Objectives . We aimed to describe the efficacy and safety of surgical management combined with C/A or C/T treatment for bone and joint infections (BJI). Patients and Methods . We conducted an observational, bi-centric study of patients treated with C/A or C/T for a BJI between May 2016 and June 2019. Failure was defined as a need for an unplanned additional antibiotic treatment or orthopedic surgery or death due to the BJI until the patient's latest visit. Results . Overall, 15 patients were included. Nine patients were treated with C/A, mainly for polymicrobial BJI due to multidrug-resistant (MDR) bacteria (Enterobacteriaceae n=7). Six patients were male; median age was 66 years-old, and median Charlson comorbidity index (CCI) was 5. It was the first septic episode on the site in 3/9 patients. Cure rate was 7/9 (median follow-up: 272 days). Two patients showed C/A-related confusion. Five patients were treated with C/T, for BJI involving MDR-Pseudomonas aeruginosa. Four patients were male; median age was 53 years-old, and median-CCI was 2. All patients had previous septic episodes on infectious site. Cure rate was 3/5 (median follow-up: 350 days). One patient was successfully treated by C/T then C/A for multistage spondylodiscitis. Conclusion . In our experience, C/A and C/T were two effective and safe options, even as salvage treatment of BJI due to MDR GNB despite the absence of label, but more data are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect